A renaissance in targeting the PI3K/AKT/mTOR pathway

Area of Science:

• Biochemistry
• Pharmacology
• Oncology

Background:

• The phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is implicated in cancer, immune regulation, and genetic disorders.
• This pathway is a validated drug target due to its significant role in cellular processes.
• Despite approved agents, drug development faces hurdles including tolerability and resistance.

Purpose of the Study:

• To review the challenges and successes in targeting the PI3K/AKT/mTOR pathway.
• To highlight recent advancements and future directions in the therapeutic modulation of this signaling cascade.
• To provide insights into overcoming resistance mechanisms and improving drug tolerability.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of pharmacological approaches and biological understanding of the PI3K/AKT/mTOR pathway.
• Synthesis of current challenges and emerging strategies in pathway targeting.

Main Results:

• The PI3K/AKT/mTOR pathway remains a promising target with significant therapeutic potential.
• Overcoming drug resistance and improving tolerability are key areas of focus.
• Novel pharmacological agents and combination therapies are under investigation.

Conclusions:

• Renewed interest and confidence exist in therapeutically modulating PI3K/AKT/mTOR signaling.
• Continued research is essential to fully exploit the therapeutic benefits of targeting this pathway.
• Improved biological and clinical understanding will drive future drug development efforts.